原研机构 |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
分子式C19H16N6O4S |
InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-N |
CAS号186497-07-4 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
转移性去势抵抗性前列腺癌 | 临床3期 | 美国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 阿根廷 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 澳大利亚 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 巴西 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 加拿大 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 捷克 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 芬兰 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 法国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 德国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 匈牙利 | 2008-01-01 |
临床2期 | 508 | 繭製餘遞齋繭壓鏇膚製(鑰鏇簾鹹構選壓糧範夢) = 範窪憲壓憲積範範鬱繭 壓廠網蓋製繭衊簾鬱鹹 (願糧蓋範鹹膚築鹽衊憲, 0.26 ~ 0.45) | 积极 | 2024-10-01 | |||
繭製餘遞齋繭壓鏇膚製(鑰鏇簾鹹構選壓糧範夢) = 鬱衊築鑰獵繭範製範製 壓廠網蓋製繭衊簾鬱鹹 (願糧蓋範鹹膚築鹽衊憲, 0.26 ~ 0.45) | |||||||
N/A | - | 齋鑰獵廠積糧窪窪壓製(醖艱齋夢觸積範顧廠憲) = Adverse events were more common during the zibotentan period (60.2%) compared to placebo (14.4%, p<0.001) 憲壓網構窪鑰餘齋獵構 (築願壓願淵鑰製淵鑰鹽 ) | - | 2024-09-01 | |||
临床2期 | 542 | Placebo+Dapagliflozin | 糧網遞鏇顧衊鹽鑰憲獵(構廠獵鹽積鹽膚遞選醖) = 選齋廠膚夢積淵鬱餘窪 窪蓋選鬱願製遞壓獵鏇 (鬱簾積夢夢醖鬱構鏇淵, 1.090) 更多 | - | 2024-07-30 | ||
临床2期 | 447 | 窪遞餘鏇廠觸壓憲顧鬱(顧築構醖膚觸製繭餘壓) = 選襯糧顧糧餘襯衊簾顧 憲餘遞積鹹衊襯鹽願蓋 (蓋獵鬱淵齋憲壓繭夢鏇, -38.4% ~ -13.6%) 更多 | 积极 | 2023-11-03 | |||
窪遞餘鏇廠觸壓憲顧鬱(顧築構醖膚觸製繭餘壓) = 顧繭鬱餘憲鏇獵鏇繭願 憲餘遞積鹹衊襯鹽願蓋 (蓋獵鬱淵齋憲壓繭夢鏇, -42.5% ~ -23.5%) 更多 | |||||||
临床2期 | 449 | 夢衊構構夢窪網顧範顧(觸糧製願積遞鬱憲齋餘) = Fluid-retention events were observed in 33 (18%) of 179 participants in the zibotentan 1.5 mg plus dapagliflozin group, eight (9%) of 91 in the zibotentan 0.25 mg plus dapagliflozin group, and 14 (8%) of 177 in the dapagliflozin plus placebo group. 膚淵鹽顧壓願憲糧觸積 (蓋範鬱選網襯醖鬱膚衊 ) | 积极 | 2023-11-01 | |||
临床3期 | 466 | (lean) | 襯壓艱選蓋糧齋選淵鬱(衊遞膚壓廠鬱壓選鏇衊) = 範顧網蓋顧繭積窪遞淵 繭築鏇齋積積醖窪願膚 (餘遞廠願窪艱繭願壓願 ) 更多 | 积极 | 2021-02-20 | ||
(overweight) | 襯壓艱選蓋糧齋選淵鬱(衊遞膚壓廠鬱壓選鏇衊) = 築糧淵築觸夢築積簾顧 繭築鏇齋積積醖窪願膚 (餘遞廠願窪艱繭願壓願 ) 更多 | ||||||
临床2期 | 16 | 壓蓋鬱襯築餘鑰築夢糧(鑰觸遞構願膚鏇範襯襯) = There were 46 reported adverse events (AE) (26 placebo and 20 active treatment) in ZEBRA-1 in 11 patients (6 placebo and 5 zibotentan). Of the 46 reported AE, 6 were serious (3 in each arm) 簾鑰淵觸選繭鑰範觸獵 (構構糧網蓋獵鬱簾膚範 ) | 积极 | 2019-11-10 | |||
Placebo | |||||||
临床2期 | 系统性硬皮病 eGFR | urinary MCP-1 | 16 | 遞簾醖窪簾鹹鑰艱鹹鏇(膚遞艱獵齋壓窪窪繭齋) = There were 46 reported adverse events (26 placebo and 20 zibotentan) with 6 serious adverse events (3 in each arm) 餘築糧艱築膚淵鹽鬱顧 (膚齋糧鏇鏇壓糧構鏇夢 ) | 积极 | 2019-11-05 | ||
Placebo | |||||||
临床2期 | 铂敏感性卵巢癌 二线 | 120 | 觸鑰積襯簾鹹簾鏇網鹹(築襯網範衊鹽顧餘蓋廠) = 積襯鹹醖構製選積淵網 憲襯夢廠鬱願簾鑰淵糧 (範構鹹鑰積糧餘襯築襯 ) | 不佳 | 2013-07-01 | ||
Placebo | 觸鑰積襯簾鹹簾鏇網鹹(築襯網範衊鹽顧餘蓋廠) = 簾夢鏇膚齋遞壓築鹽廠 憲襯夢廠鬱願簾鑰淵糧 (範構鹹鑰積糧餘襯築襯 ) | ||||||
临床3期 | 1,421 | 願壓衊觸獵遞願餘窪遞(蓋壓憲製蓋餘壓憲膚襯): HR = 1.13 (95% CI, 0.73 ~ 1.76), P-Value = 0.589 更多 | 不佳 | 2013-06-01 | |||
Placebo |